Non-Invasive Treatment of ALS Using Motor Neuron Hyperexcitability Suppression by Dr. Nader Yaghoubi

Dr. Nader Yaghoubi, M.D., Ph.D., is Co-Founder and CEO of PathMaker Neurosystems. He has over 20 years of experience in the creation, operations and financing of life science companies, and established PathMaker to pioneer a new approach to restoring damaged neural pathways. At PathMaker, he serves as Principal Investigator on a NIH-funded stroke trial and a recently launched ALS trial funded by MDA, and has led the company to a number of international awards and prizes. He previously co-founded and served as CEO of Symbiotix Biotherapies, and was the first employee at Selecta Biosciences (Nasdaq:SELB) and BIND Therapeutics (Nasdaq:BIND). Earlier, he was at Zero Stage Capital and completed an internship at Advent International. He completed a Fellowship in Health Care Entrepreneurship at Boston University, and served as a resident in the Department of Surgery at Lenox Hill Hospital in New York. Dr. Yaghoubi received an M.D. and Ph.D. in Molecular Pharmacology from the combined degree program at Boston University School of Medicine, and did his undergraduate studies in Biochemistry at the University of Arizona.